Changeflow GovPing Healthcare & Life Sciences EP4157822A1 Heterocyclic SOCE Inhibitors Patent...
Routine Rule Added Final

EP4157822A1 Heterocyclic SOCE Inhibitors Patent, Apr 15, 2026

Favicon for changeflow.com EPO Patent Bulletin - Organic Chemistry (C07D)
Published
Detected
Email

Summary

The European Patent Office published application EP4157822A1 for heterocyclic SOCE (Store-Operated Calcium Entry) inhibitors and therapeutic uses thereof. The application names six inventors across six French research institutions including INSERM, CNRS, and Université de Rennes as applicants. The claimed compounds span multiple therapeutic categories including cardiovascular, respiratory, dermatological, musculoskeletal, neurological (including dementia), and anti-inflammatory applications, as indicated by the A61P classification codes. A1 publication kind code confirms the application was published with the European search report.

Published by EPO on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

About this source

GovPing monitors EPO Patent Bulletin - Organic Chemistry (C07D) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 63 changes logged to date.

What changed

The EPO published European patent application EP4157822A1 for heterocyclic SOCE inhibitors filed by six French research institutions (INSERM, Université de Brest, Ecole Nationale Supérieure de Chimie de Rennes, Institut National des Sciences Appliquées de Rennes, Université Nangui Abrogoua, and CNRS/Université de Rennes). The application covers therapeutic uses of heterocyclic compounds that inhibit store-operated calcium entry, with claims spanning multiple A61P therapeutic categories from cardiovascular and respiratory conditions to neurological disorders and anti-inflammatory applications.

For pharmaceutical manufacturers and biotech companies researching calcium signaling pathways, this publication establishes a prior art date and territorial scope across 17 designated European Patent Convention member states. Competitors developing SOCE-modulating compounds for similar therapeutic indications should review freedom-to-operate implications. Research institutions may consider this when designing around or licensing programs for calcium channel-targeted drug development.

Archived snapshot

Apr 26, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← EPO Patent Bulletin

SOCE INHIBITORS AND THERAPEUTIC USES THEREOF

Publication EP4157822A1 Kind: A1 Apr 15, 2026

Applicants

Institut National de la Santé et de la
Recherche Médicale (INSERM), Université de Brest, Ecole Nationale Superieure de Chimie de Rennes, Institut National des Sciences Appliquées de
Rennes, Universite Nangui Abrogoua, Centre National de la Recherche Scientifique
(CNRS), Université de Rennes

Inventors

BAZUREAU, Jean Pierre, DAGO, Déliko Camille, VOLI, Lou Anne, MIGNEN, Olivier, BRIGADEAU, Christophe, BEKRO, Yves-Alain

IPC Classifications

C07D 231/12 20060101AFI20230224BHEP C07D 231/56 20060101ALI20230224BHEP C07D 235/06 20060101ALI20230224BHEP C07D 235/10 20060101ALI20230224BHEP C07D 249/08 20060101ALI20230224BHEP C07D 405/12 20060101ALI20230224BHEP A61K 31/415 20060101ALI20230224BHEP A61K 31/416 20060101ALI20230224BHEP A61K 31/4184 20060101ALI20230224BHEP A61K 31/4196 20060101ALI20230224BHEP A61P 7/02 20060101ALI20230224BHEP A61P 1/18 20060101ALI20230224BHEP A61P 9/00 20060101ALI20230224BHEP A61P 11/00 20060101ALI20230224BHEP A61P 11/06 20060101ALI20230224BHEP A61P 17/06 20060101ALI20230224BHEP A61P 19/00 20060101ALI20230224BHEP A61P 19/02 20060101ALI20230224BHEP A61P 21/00 20060101ALI20230224BHEP A61P 25/28 20060101ALI20230224BHEP A61P 29/00 20060101ALI20230224BHEP

Designated States

AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR

View original document →

Get daily alerts for EPO Patent Bulletin - Organic Chemistry (C07D)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from EPO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
EPO
Published
April 15th, 2026
Instrument
Rule
Branch
International
Legal weight
Binding
Stage
Final
Change scope
Minor

Who this affects

Applies to
Manufacturers
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Patent application Drug compound research Therapeutic development
Geographic scope
European Union EU

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Healthcare Pharmaceuticals

Get alerts for this source

We'll email you when EPO Patent Bulletin - Organic Chemistry (C07D) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!